Compare Janus Living Inc. Class A-1 Common Stock (JAN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Janus Living Inc. Class A-1 Common Stock vs Smith & Nephew plc — how do they compare? Janus Living Inc. Class A-1 Common Stock trades at $28.51 (market cap $6.76B), while Smith & Nephew plc trades at $28.45 (market cap $11.60B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals — on Pluang, investors hold Janus Living Inc. Class A-1 Common Stock for 0 Days and Smith & Nephew plc for 121 Days on average.
| JAN | SNN | |
|---|---|---|
Market Cap | $6.76B | $11.60B |
Volume | 1,332,082 | 971,836 |
Sector | Real Estate | Health |
52-Week High | $31.76 | $37.17 |
52-Week Low | $22.88 | $26.42 |
Typical Hold Time | 0 Days | 121 Days |
Enterprise Value | $6.85B | $14.63B |
Dividend Yield | 1.98% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
SNN trades at $27.88, near its 52-week low, with a mixed technical signal but improving fundamentals. Revenue grew to $6.16B in 2025, with net income margin expanding to 10.08%. Recent product launches like the EVOS PELVIC System and FLOW FLEXTEND COBLATION Wand highlight innovation, though the stock faces bearish moving averages and neutral oscillators.
Outlook is cautious; strong profitability and cash flow support value, but analyst consensus is predominantly Hold amid competitive pressures and recent CFO departure. Risks include execution challenges and debt levels, yet institutional interest from BlackRock's $505M investment signals confidence. The stock offers potential for recovery if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
